June 5, 2022 11:07 AM EDT
R&D

#AS­CO22: In yet an­oth­er sting­ing set­back, Pfiz­er’s block­buster CDK 4/6 fails its lat­est test on sur­vival. But can No­var­tis and Eli Lil­ly ben­e­fit?

John Carroll

Editor & Founder

In the lat­est in a se­ries of big clin­i­cal set­backs, Pfiz­er re­port­ed at AS­CO that its close­ly watched PALO­MA-2 Phase III study of Ibrance com­bined …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times